Abstract
Background Studying the phenotypic and genetic characteristics of age and polarity at onset (AAO, PAO) in bipolar disorder (BD) can provide new insights into disease pathology and facilitate the development of screening tools.
Aims To examine the genetic architecture of AAO and PAO and their association with BD disease characteristics.
Methods Genome-wide association studies (GWASs) and polygenic score (PGS) analyses of AAO (N=12977) and PAO (N=6773) were conducted in BD patients of 34 cohorts and a replication sample (N=2237). The association of onset with disease characteristics was investigated in two of these cohorts.
Results Earlier AAO was associated with an increased risk of psychotic symptoms, suicidality, and fewer episodes. A depressive onset correlated with lifetime suicidality and a manic onset with delusions and manic episodes. Systematic differences in AAO between cohorts and continents of origin were observed. This was also reflected in SNV-based heritability estimates, with higher heritabilities for stricter onset definitions. Increased polygenic scores for autism spectrum disorder (β=-0.34 years, SE=0.08), major depression (β=-0.34 years, SE=0.08), schizophrenia (β=-0.39 years, SE=0.08), and educational attainment (β=-0.31 years, SE=0.08) were associated with an earlier AAO. The AAO GWAS identified one significant locus, but this finding did not replicate. Neither GWAS nor PGS analyses yielded significant associations with PAO.
Conclusions AAO and PAO are associated with indicators of BD severity. Individuals with an earlier onset show an increased polygenic liability for a broad spectrum of psychiatric traits. Systematic differences in AAO across cohorts, continents, and phenotype definitions introduce significant heterogeneity, affecting analyses.
RELEVANCE STATEMENT In the largest study to systematically characterize age at onset (N=12977) and polarity at onset (N=6773) in bipolar disorder, we describe an association between illness onset characteristics and indicators of severity, confirming their clinical relevance. Our study shows that that early illness onset is associated with genetic liability for a broad range of psychiatric disorders. However, we also highlight systematic differences in age at onset across cohorts, continents, and phenotype definitions. This heterogeneity results in reduced heritability and affects genetic analyses, underscoring the need for the development of standardized phenotype definitions.
Competing Interest Statement
Amare T. Azmeraw: Dr Amare has received 2020-2022 NARSAD Young Investigator Grant from the Brain & Behaviour Research Foundation. Ole A. Andreassen: Speaker's honorarium Sunovion, Lundbeck. Consultant HealthLytix Bernhard Baune: Honoraria: Lundbeck, Janssen, LivaNova, Servier Carrie Bearden: Novartis Scientific Advisory Board Clark Scott: Honoraria and Investigator Initiated project funding from Jannsen-Cilag Australia, Lundbeck-Otsuka Australia J. Raymond DePaulo: owns stock in CVS Health; JRD was unpaid consultant for Myriad Neuroscience 2017 & 2019 Michael C. O Donovan: Research unrelated to this manuscript supported by a collaborative research grant from Takeda Pharmaceuticals Bruno Etain: Honoraria for Sanofi Mark A. Frye: Grant Support Assurex Health, Mayo Foundation, Medibio Consultant (Mayo) Actify Neurotherapies, Allergan, Intra-Cellular Therapies, Inc., Janssen, Myriad, Neuralstem Inc., Sanofi, Takeda, Teva Pharmaceuticals Per Hoffmann: Employee of Life&Brain GmbH, Member of the Scientific Advisory Board of HMG Systems Engeneering GmbH Mikael Landen: Speaker's honoraria Lundbeck pharmaceuticals Andrew M McIntosh: Research funding from The Sackler Trust, speaker fees from Illumina and Janssen Philip B. Mitchell: Remuneration for lectures in China on bipolar disorder research by Sanofi (Hangzhou) John Nurnberger: Investigator for Janssen Benjamin M. Neale: Is a member of the scientific advisory board at Deep Genomics and RBNC Therapeutics. A consultant for Camp4 Therapeutics, Takeda Pharmaceutical and Biogen. Andreas Reif: Speaker's honoraria / Advisory boards: Janssen, Shire/Takeda, Medice, SAGE and Servier Eli Stahl: now employed by the Regeneron Genetics Center. Kato Tadafumi: Honoraria: Kyowa Hakko Kirin Co., Ltd., Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Taisho Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd., Pfizer Japan Inc., Mochida Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Janssen Pharmaceutical K.K., Janssen Asia Pacific, Yoshitomiyakuhin, Astellas Pharma Inc., Nippon Boehringer Ingelheim Co. Ltd., MSD K.K., Kyowa Pharmaceutical Industry Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eisai Co., Ltd. Grants: Takeda Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation. Eduard Vieta: Has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi-Aventis, Sunovion, and Takeda. None of the other Authors reported any biomedical financial interests or potential conflicts of interest.
Funding Statement
The authors thank Jacquie Klesing, Board-certified Editor in the Life Sciences (ELS), for editing assistance with the manuscript. BOMA-Australia sample: We thank Gin Mahli, Colleen Loo, and Micheal Breaskpear for their contribution to clinical assessments of a subset of patients and also Andrew Frankland for his work in collating clinical record data. WTCCC sample: This study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. French sample: We thank the psychiatrists and psychologists who participated in the clinical assessment of patients in France (C. Henry, S. Gard, JP Kahn, L Zanouy, RF Cohen and O. Wajsbrot‐Elgrabli) and thank the patients for their participation. 7. Funding Loes M. Olde Loohuis: NIH K99/R00 MH116115. Eli Stahl: NIH U01MH109536; E.S. is now employed by the Regeneron Genetics Center. Andrew McQuillin: Medical Research Council, Grant/Award Numbers: G0500791, G0701007, G0801038, G1000708, G9623693N; Stanley Center for Psychiatric Research at the Broad Institute Douglas Ruderfer: R01MH116269 Maria Grigoroiu-Serbanescu: UEFISCDI, Romania, several grants Tim B Bigdeli: NIH MH085548, MH085542, MH104564 Fabian Streit: BMBF grant 01EW1810 ERA-Net Neuron "Synschiz", BMBF grant 01ZX1614G e:Med Integrament Mark J Adams: Wellcome Trust 104036/Z/14/Z, MRC MC_PC_17209 Rolf Adolfsson: Swedish Research Council (2009-33891-68296-196) and the Swedish Federal Government under the LUA/ALF agreement (ALF; RV-161691) Ole A. Andreassen: Norwegian Research Council, KG Jebsen Stiftelsen, South-Eastern Norway Health Authority Ceylan Balaban: BMBF "BipoLife" Subproject TPP1 Frank Bellivier: INSERM (Institut National de la Sante et de la Recherche Medicale - C0829), AP-HP (Assistance Publique des Hopitaux de Paris - RBM0436), Fondation FondaMental (RTRS Sante Mentale), Labex Bio-PSY (Investissements dAvenir program managed by the ANR under reference ANR-11-IDEX- 0004-02). Antonio Benabarre: Thanks the support of the Spanish Ministry of Science and Innovation (PI17/01122) Wade Berrettini: R01 MH078156 Evelyn J Bromet: NIH MH085548, MH085542, MH104564 Sven Cichon: European Union Horizon 2020 Research and Innovation Programme (grant 785907 (HBP SGA2)), BMBF grant 01ZX1314Ae:Med Integrament, Swiss National Science Foundation (SNSF) grant 156791 William Coryell: R01 MH078154 Nick Craddock: Wellcome Trust (grant #078901) David Craig: R01 MH078159 Paul E. Croarkin: National Institue of Mental Health (NIMH) R01 MH113700 Udo Dannlowski: This work was funded by the German Research Foundation (DFG, grant FOR2107 DA1151/5-1 and DA1151/5-2 to UD; SFB-TRR58, Projects C09 and Z02 to UD) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Munster (grant Dan3/012/17 to UD). Franziska Degenhardt: German Federal Ministry of Education and Research (BMBF) within the e:Med programme (grant COMMITMENT) and the EU COST (European Cooperation in Science and Technology) programme (COST Action EnGagE CA17130). Bruno Etain: INSERM (Institut National de la Sante et de la Recherche Medicale - C0829), AP-HP (Assistance Publique des Hopitaux de Paris - RBM0436), Fondation FondaMental (RTRS Sante Mentale), Labex Bio-PSY (Investissements dAvenir program managed by the ANR under reference ANR-11-IDEX- 0004-02). Ayman H Fanous: NIH MH085548, MH085542, MH104564 Janice M. Fullerton: National Health and Medical Research Council (Australia) grants 1037196,1063960, 1066177; and The Janette Mary ONeil Research Fellowship Julie Garnham: Canadian Institutes of Health Research (grant #166098); Dalhousie Medical Research Foundation, Genome Atlantic, Lindsay family fund Elliot Gershon: R01 MH078153 Tim Hahn: TH was supported by the German Research Foundation (DFG grants HA7070/2-2, HA7070/3, HA7070/4) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Munster (MzH3/020/20). Stephane Jamain: INSERM (Institut National de la Sante et de la Recherche Medicale - C0829), AP-HP (Assistance Publique des Hopitaux de Paris - RBM0436), Fondation FondaMental (RTRS Sante Mentale), Labex Bio-PSY (Investissements dAvenir program managed by the ANR under reference ANR-11-IDEX- 0004-02). Esther Jimenez: EJ thanks the support of the Spanish Ministry of Science and Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdireccin General de Evaluacin and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria dUniversitats i Recerca del Departament dEconomia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. Ian Jones: Wellcome Trust (grant #078901) Lisa Jones: Wellcome Trust (grant #078901) John R. Kelsoe: R01 MH078151 Tilo Kircher: This work was funded by the German Research Foundation (DFG, grant FOR2107 KI588/14-1 and FOR2107 KI588/14-2 to TK) George Kirov: Recriutment of the Bulgarian Trios was funded by the Janssen Research Foundation James A Knowles: NIH MH085548, MH085542, MH104564 Thorsten Kranz: BMBF "BipoLife" Subproject TPP1 Trine Vik Lagerberg: Norwegian Research Council (grant #288542) Mikael Landen: The Stanley Center for Psychiatric Research, Broad Institute from a grant from Stanley Medical Research Institute, the Swedish Research Council (2018-02653), the Swedish foundation for Strategic Research (KF10-0039), the Swedish Brain foundation (FO2020-0261), and the Swedish Federal Government under the LUA/ALF agreement (ALF 20170019, ALFGBG-716801). William Lawson: R01 MH078161 Marion Leboyer: INSERM (Institut National de la Sante et de la Recherche Medicale - C0829), AP-HP (Assistance Publique des Hopitaux de Paris - RBM0436), Fondation FondaMental (RTRS Sante Mentale), Labex Bio-PSY (Investissements dAvenir program managed by the ANR under reference ANR-11-IDEX- 0004-02). Dolores MAlaspina: NIH MH085548, MH085542, MH104564 Melvin McInnis: R01 MH078162 Andrew M McIntosh: Wellcome Trust 104036/Z/14/Z, MRC MC_PC_17209 Helena Medeiros: NIH MH085548, MH085542, MH104564 Ingrid Melle: "Regional Health Authority South-Eastern Norway (grants # 2015088,2018093)" Vihra Milanova: Recriutment of the Bulgarian Trios was funded by the Janssen Research Foundation Philip B. Mitchell: National Health and Medical Research Council (Australia) grants 1037196, 1177991 John Nurnberger: R01 MH078152 Carlos Pato: NIH MH085548, MH085542, MH104564 Michele T Pato: NIH MH085548, MH085542, MH104564 James B. Potash: R01 MH078157 Mark H Rapaport: NIH MH085548, MH085542, MH104564 Andreas Reif: BMBF "BipoLife" Subproject TPP1 Marcella Rietschel: BMBF grant 01EW1810 ERA-Net Neuron "Synschiz", BMBF grant 01EW1904 ERA-Net Neuron "Embed", BMBF grant 01ZX01909A e:Med SysmedSUD, BMBF grant 01ZX1614G e:Med Integrament Gloria Roberts: National Health and Medical Research Council (Australia) grants 1037196 Guy Rouleau: Canadian Institutes of Health Research (grant #166098) William A. Scheftner: R01 MH078155 Peter R. Schofield: National Health and Medical Research Council (Australia) grants 1037196,1063960, 1176716 Janet L Sobell: NIH MH085548, MH085542, MH104564 John Strauss: Canadian Institutes of Health Research, MOP-172013 Gustavo Turecki: Canadian Institutes of Health Research (grant #166098) Eduard Vieta: EV thanks the support of the Spanish Ministry of Science and Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdireccin General de Evaluacin and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria dUniversitats i Recerca del Departament dEconomia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. John B. Vincent: Canadian Institutes of Health Research, MOP-172013 Jordan W Smoller: R01MH063445 Francis J. McMahon: Funded in part by the Intramural Research Program of the NIMH (ZIA MH002843) Martin Alda: Canadian Institutes of Health Research (grant #166098); Dalhousie Medical Research Foundation, Genome Atlantic, Lindsay family fund Till. F. M. Andlauer: German Federal Ministry of Education and Research (BMBF) through the DIFUTURE consortium of the Medical Informatics Initiative Germany (grant 01ZZ1804A) and the Integrated Network IntegraMent, under the auspices of the e:Med Programme (grant 01ZX1614J), as well as the European Unions Horizon 2020 Research and Innovation Programme (grant MultipleMS, EU RIA 733161) The Collection of the Dutch cohort was funded through NIMH R01MH090553 awarded to Dr. Ophoff. The collection of the Colombian samples was funded through NIMH R01 MH113078 awarded to Drs. Lopez-Jaramillo, Bearden and Freimer. The collection of the BOMA-Australia sample (bip_bmau_eur) was supported by the Australian National Medical and Health Research Council (NHMRC) Program Grant 1037196 and Project Grants 1063960 and 1066177. DNA was extracted by Genetic Repositories Australia, an Enabling Facility that was supported by NHMRC Enabling Grant 401184. We gratefully acknowledge the Janette Mary ONeil Research Fellowship (to JMF). We acknowledge support from NHMRC Investigator Grants (Leadership 3) to PBM (1177991) and PRS (1176716). Funding for the project was provided by the Wellcome Trust under award 076113, 085475 and 090355. The work by the French group was supported by INSERM (Institut National de la Sante et de la Recherche Medicale - C0829), AP-HP (Assistance Publique des Hopitaux de Paris - RBM0436), the Fondation FondaMental (RTRS Sante Mentale), and the labex Bio-PSY (Investissements dAvenir program managed by the ANR under reference ANR-11-IDEX- 0004-02).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
An overview of the ethical oversight for the individual cohorts is in Supplement_Ethics.xlsx. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects/patients were approved by the local ethics committees, and written informed consent was obtained from all subjects/patients.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary statistics for our meta-analysis of the GWAS cohort samples will be available through the PGC (https://www.med.unc.edu/pgc/download-results/).
